Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001193125-17-116502
Filing Date
2017-04-07
Accepted
2017-04-07 17:24:59
Documents
62
Period of Report
2016-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q/A d368395d10qa.htm 10-Q/A 742080
2 EX-31.1 d368395dex311.htm EX-31.1 6629
3 EX-31.2 d368395dex312.htm EX-31.2 6514
4 EX-32 d368395dex32.htm EX-32 5647
  Complete submission text file 0001193125-17-116502.txt   5117472

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT insy-20160930.xml EX-101.INS 1307967
6 XBRL TAXONOMY EXTENSION SCHEMA insy-20160930.xsd EX-101.SCH 38186
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE insy-20160930_cal.xml EX-101.CAL 59878
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE insy-20160930_def.xml EX-101.DEF 276354
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE insy-20160930_lab.xml EX-101.LAB 322545
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE insy-20160930_pre.xml EX-101.PRE 328078
Mailing Address 10220 SOUTH 51ST STREET SUITE 2 PHOENIX AZ 85044
Business Address 10220 SOUTH 51ST STREET SUITE 2 PHOENIX AZ 85044 602-910-2617
Insys Therapeutics, Inc. (Filer) CIK: 0001516479 (see all company filings)

EIN.: 510327886 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q/A | Act: 34 | File No.: 001-35902 | Film No.: 17750839
SIC: 2834 Pharmaceutical Preparations